Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLTAES)

Drug Name

MK-0752 Drug Info

Synonyms

MK-0752; 471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]

Cross-matching ID

PubChem CID: 9803433
CAS Number: CAS 471905-41-6
TTD Drug ID: DMLTAES

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Gamma-secretase (GS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nirogacestat	DMUP5Z0	Desmoid tumour	2F7C	Approved	[2]
(S)-FLURBIPROFEN	DMF2O4T	Myalgia	FB56.2	Preregistration	[3]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[4]
Semagacestat	DML83IW	Parkinson disease	8A00.0	Phase 3	[5]
R-flurbiprofen	DMFIVSR	N. A.	N. A.	Phase 2	[3]
BMS-708163	DM51LTG	Alzheimer disease	8A20	Phase 2	[6]
CHF-5074	DMTE071	Alzheimer disease	8A20	Phase 2	[7]
RO-4929097	DMXA6B3	Breast cancer	2C60-2C65	Phase 2	[8]
AL102	DMCTWIB	Desmoid tumour	2F7C	Phase 2	[9]
SPI-014	DM5IPUS	Alzheimer disease	8A20	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gamma-secretase (GS)	TT9W8GU	APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52.
2	Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77.
3	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
4	Clinical pipeline report, company report or official report of Roche (2009).
5	A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50.
6	Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40.
7	CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93.
8	Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53.
9	Clinical pipeline report, company report or official report of Ayala Pharmaceuticals.
10	Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:210756.